UK gene therapy company Nightstar Therapeutics prices IPO at $14 midpoint – Nasdaq
|
UK gene therapy company Nightstar Therapeutics prices IPO at $14 midpoint
Nasdaq Nightstar Therapeutics, a UK biotech developing gene therapies for rare retinal diseases, raised $75 million by offering 5.4 million shares at $14, at the midpoint of $13 to $15 targeted range. Nightstar Therapeutics plans to list on the Nasdaq under … |
